North America Vaccines Market worth $35.68 billion by 2030
The report "North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030" The North America vaccines market is projected to reach USD 35.68 billion by 2030 from USD 25.29 billion, at a CAGR of 7.1% during the forecast period. The North American vaccine market is experiencing growth, driven by several key factors, including the high prevalence of infectious diseases, an emphasis on preventive healthcare, and technological advancements in vaccine development.
Browse 290 market data Tables and 30 Figures spread through 250 Pages and in-depth TOC on "North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/north-america-vaccines-market-38578224.html
Pneumococcal disease accounted for the largest share of the North American vaccines market by disease indication in 2024.
By disease indication, the North America vaccines market is divided into pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, and other disease indications. In 2024, pneumococcal disease accounted for the largest share in the North American vaccines market by disease indication. This growth arises from elevated infection rates, recommendations for vulnerable groups, alongside ongoing advances in conjugate and polysaccharide formulations, and heightened awareness of pneumonia fatalities, which have fueled worldwide demand.
Pediatric vaccines are estimated to register the faster growth in the North America vaccines market by end user during the forecast period.
By end user, the market is divided into pediatric vaccines and adult vaccines. During the forecast period, pediatric vaccines experienced the fastest growth in the end user vaccines market. The elevated incidence of childhood infectious diseases, their prominent role in national immunization agendas, and aggressive global campaigns by WHO and UNICEF to boost vaccination rates among children, and factors like innovative combination vaccines that minimize injections, greater parental recognition of early immunization benefits, and surging public and private-sector funding for pediatric programs, are accelerating this segment's momentum.
The US accounted for the largest regional share in the North America vaccines market (excluding COVID-19) in 2024.
The North American vaccine market is segmented into the US and Canada. The US held the largest share in the North American vaccines market, mainly due to the advanced immunization infrastructure, high vaccination rates across pediatric and adult populations, substantial investments in research and development, and robust government backing for routine immunization programs. The US is expected to maintain leadership moving forward.
Key players in the North America vaccines market are Merck & Co., Inc. (US), Pfizer, Inc. (US), GSK Plc (UK), Johnson & Johnson Services, Inc. (US), Sanofi (France), CSL (Australia), Emergent BioSolutions (US), and Novavax, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ’GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the North America Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
